Inventor · disambiguated record
Gary A. Decrescenzo
Also filed as: DECRESCENZO GARY · DECRESCENZO GARY A · DECRESCENZO GARY ANTHONY
159 granted patents·27 pending applications·2,318 citations·filing 1989–2025
99Inventor score
Files withSEARLE & CO99MONSANTO CO17PHARMACIA CORP17BIOMED VALLEY DISCOVERIES INC14ACLARIS THERAPEUTICS INC8
Top patents by PatentIndex Score
186 records- 0198US6248775B1α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 1999·Granted Jun 19, 2001·129 cites·18 claims
- 0298US6060476Aα- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 1994·Granted May 9, 2000·77 cites·12 claims
- 0397US5965588ASulfonylalkanoylamino hydroxyethylamimo sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 1998·Granted Oct 12, 1999·66 cites·20 claims
- 0497US5744481Aβ-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 1997·Granted Apr 28, 1998·51 cites·47 claims
- 0596US9765142B2TEM8 antibodies and their use in treatment and detection of tumorsUS HEALTH·Filed 2014·Granted Sep 19, 2017·31 cites·49 claims
- 0696US5968942Aα- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 1994·Granted Oct 19, 1999·61 cites·23 claims
- 0795US6472407B1α and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 2000·Granted Oct 29, 2002·21 cites·20 claims
- 0895US6335460B1α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 2000·Granted Jan 1, 2002·28 cites·26 claims
- 0995US5843946Aα-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 1993·Granted Dec 1, 1998·78 cites·14 claims
- 1095US5482947ARetroviral protease inhibitorsFiled 1993·Granted Jan 9, 1996·38 cites·18 claims
- 1194US7320983B2α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE LLC·Filed 2006·Granted Jan 22, 2008·8 cites·16 claims
- 1294US7141609B2α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 2005·Granted Nov 28, 2006·13 cites·20 claims
- 1394US6500832B1α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 2000·Granted Dec 31, 2002·21 cites·20 claims
- 1493US6846954B2α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 2002·Granted Jan 25, 2005·16 cites·14 claims
- 1593US6417387B1α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 2001·Granted Jul 9, 2002·24 cites·1 claims
- 1693US5508294ASulfonylalkanoylamino hydroxyethlamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 1995·Granted Apr 16, 1996·41 cites·11 claims
- 1792US7115618B2α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 2004·Granted Oct 3, 2006·12 cites·13 claims
- 1892US6534493B1α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 2000·Granted Mar 18, 2003·26 cites·29 claims
- 1991US7829564B2α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE LLC·Filed 2007·Granted Nov 9, 2010·4 cites·16 claims
- 2091US7115632B1Sulfonyl aryl or heteroaryl hydroxamic acid compoundsSEARLE & CO·Filed 2000·Granted Oct 3, 2006·33 cites·55 claims
- 2191US6924286B1α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 2003·Granted Aug 2, 2005·16 cites·20 claims
- 2290US7339078B2Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitorsSEARLE LLC·Filed 2006·Granted Mar 4, 2008·6 cites·18 claims
- 2390US7161033B2Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitorsSEARLE & CO·Filed 2005·Granted Jan 9, 2007·6 cites·20 claims
- 2490US6869951B1Method of changing conformation of a matrix metalloproteinasePHARMACIA CORP·Filed 2000·Granted Mar 22, 2005·60 cites·29 claims
- 2590US6646010B2α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 2002·Granted Nov 11, 2003·16 cites·12 claims
- 2690US6022872Aα- and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitorsSEARLE & CO·Filed 1996·Granted Feb 8, 2000·27 cites·42 claims
- 2790US5610190ARetroviral protease inhibitorsSEARLE & CO·Filed 1995·Granted Mar 11, 1997·27 cites·48 claims
- 2890US5578606Aα- and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitorsSEARLE & CO·Filed 1992·Granted Nov 26, 1996·27 cites·6 claims
- 2990US5510388ASulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 1995·Granted Apr 23, 1996·27 cites·16 claims
- 3089US11767309B2Methods of synthesizing substituted pyridinone-pyridinyl compoundsACLARIS THERAPEUTICS INC·Filed 2021·Granted Sep 26, 2023·1 cites·36 claims
- 3189US6172082B1α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 1995·Granted Jan 9, 2001·24 cites·49 claims
- 3288US11844801B2Oral compositions of MK2 pathway inhibitor for treatment of immune conditionsACLARIS THERAPEUTICS INC·Filed 2021·Granted Dec 19, 2023·2 cites·64 claims
- 3388US10604582B2Anti-CD276 antibodies (B7H3)THE US SECRETARY DEPARTMENT OF HEALTH·Filed 2015·Granted Mar 31, 2020·4 cites·37 claims
- 3488US7531538B2α- and β-Amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE LLC·Filed 2006·Granted May 12, 2009·6 cites·19 claims
- 3588US6750228B1Aromatic sulfone hydroxamic acid metalloprotease inhibitorPHARMACIA CORP·Filed 2000·Granted Jun 15, 2004·35 cites·44 claims
- 3687US11246859B2Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancersBIOMED VALLEY DISCOVERIES INC·Filed 2017·Granted Feb 15, 2022·2 cites·3 claims
- 3787US10881646B2Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancersBIOMED VALLEY DISCOVERIES INC·Filed 2017·Granted Jan 5, 2021·2 cites·12 claims
- 3887US6455581B1α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 1995·Granted Sep 24, 2002·20 cites·26 claims
- 3987US6022994ASuccinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 1998·Granted Feb 8, 2000·23 cites·40 claims
- 4087US5025021A1,2-dideoxy-2-fluoronojirimycin as glycosidase inhibitorsMONSANTO CO·Filed 1989·Granted Jun 18, 1991·22 cites·19 claims
- 4186USRE43596Eα- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsVAZQUEZ MICHAEL L·Filed 2007·Granted Aug 21, 2012·3 cites·15 claims
- 4286US6683093B2Aromatic sulfone hydroxamic acids and their use as protease inhibitorsPHARMACIA CORP·Filed 2001·Granted Jan 27, 2004·27 cites·93 claims
- 4386US5521219ASulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 1993·Granted May 28, 1996·54 cites·13 claims
- 4485US6313345B1Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 1999·Granted Nov 6, 2001·19 cites·172 claims
- 4585US5786483Aα-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitorsSEARLE & CO·Filed 1995·Granted Jul 28, 1998·26 cites·28 claims
- 4685US5026713A1,3-dideoxy-3-fluoronojirimycin which inhibits glycosidase activityMONSANTO CO·Filed 1989·Granted Jun 25, 1991·19 cites·27 claims
- 4785US2024374604A1Cancer treatments using combinations of cdk and erk inhibitorsBIOMED VALLEY DISCOVERIES INC·Filed 2024·Application pending·0 cites
- 4884US12076324B2Cancer treatments using combinations of CDK and ERK inhibitorsBIOMED VALLEY DISCOVERIES INC·Filed 2023·Granted Sep 3, 2024·0 cites·24 claims
- 4984US5703076ARetroviral protease inhibitorsSEARLE & CO·Filed 1995·Granted Dec 30, 1997·23 cites·35 claims
- 5083US11007184B2Cancer treatments using combinations of type 2 MEK and ERK inhibitorsBIOMED VALLEY DISCOVERIES INC·Filed 2014·Granted May 18, 2021·3 cites·33 claims
Showing the top 50 of 186 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →